Furmonertinib-based triplet therapy improves survival in EGFR-mutant NSCLC with leptomeningeal metastases: a large-scale multicenter retrospective study (FURMO-LM)

Submitted by Anonymous on

Abstract Background: Leptomeningeal metastases (LM) in epidermal growth factor receptor mutant (EGFRm) non-small-cell lung cancer (NSCLC) represent a major therapeutic challenge. Despite the improved central nervous system penetration of third-generation EGFR tyrosine kinase inhibitors (TKIs), key uncertainties persist regarding the...

Impact of prophylactic skin toxicity management on treatment continuity and clinical outcomes in EGFR-mutant non-small cell lung cancer treated with osimertinib: a 7-year real-world retrospective cohort study

Submitted by Anonymous on

AbstractIntroduction Osimertinib is the preferred epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) for patients with EGFR-mutant non-small cell lung cancer (NSCLC) due to its superior efficacy and favorable safety profile. Nevertheless, dermatologic toxicities remain common and may disrupt treatment...

The Bull Case For Vera Therapeutics (VERA) Could Change Following FDA Alignment On Earlier ORIGIN 3 eGFR Analysis

Submitted by Anonymous on

Earlier in June 2026, Vera Therapeutics announced that it had reached alignment with the U.S. FDA on a revised, earlier eGFR analysis plan for the ORIGIN 3 trial of atacicept in adults with IgA nephropathy, with key results now expected...

Synthesis, spectroscopic characterization, DFT analysis, and EGFR docking studies of novel Schiff base derivatives

Submitted by Anonymous on

Abstract Schiff bases represent a highly reactive class of functional groups with significant biological importance and extensive chemical diversity, making them a focus of active research in both material and medicinal chemistry. This work reports the synthesis of novel Schiff...

CStone Launches Global Phase I Trial for New EGFR/HER3 Bispecific ADC

Submitted by Anonymous on

CStone Pharmaceuticals ( ($HK:2616) ) has shared an update. CStone Pharmaceuticals has initiated global clinical development of CS5007, an EGFR/HER3 bispecific anti Introducing TipRanks MCP for Agents Deliver institutional-grade market data directly into Claude, ChatGPT, Cursor, and other MCP-compatible AI...

Rational design and insilico evaluation of 2-amino-5-methylthiazole derivatives as potent EGFR inhibitors for colorectal cancer therapy

Submitted by Anonymous on

Article summary AI generated Colorectal cancer (CRC) is a significant global health issue, primarily driven by the epidermal growth factor receptor (EGFR), which plays a crucial role in tumor progression. This study successfully designed and evaluated a series of 2-amino-5-methylthiazole...

Dual-template structure-based design of novel harmine derivatives as EGFR inhibitors for colorectal cancer therapy

Submitted by Anonymous on

Abstract Colorectal cancer (CRC) remains a major global health challenge, underscoring the urgent need for novel and effective therapeutic agents. In this study, a dual-template, structure-based drug design strategy was employed to develop fourteen novel harmine-derived inhibitors targeting the Epidermal...

Surgical Removal of Residual Tumor Masses in Patients Undergoing Targeted Therapy for EGFR‐Mutated Locally Advanced or Metastatic Lung Cancer

Submitted by Anonymous on

International Journal of CancerEarly View RESEARCH ARTICLE Surgical Removal of Residual Tumor Masses in Patients Undergoing Targeted Therapy for EGFR-Mutated Locally Advanced or Metastatic Lung Cancer Fedor Moiseenko, Corresponding Author Fedor Moiseenko moiseenkofv@gmail.com N.P Napalkov Cancer Center, St.-Petersburg, Russia N.N....

Subscribe to Newsfeed